[{"id":"08b2bc8f-c536-4ab4-95bd-8afe3b23bcd7","acronym":"NRG-GY026","url":"https://clinicaltrials.gov/study/NCT05256225","created_at":"2022-02-25T17:52:52.661Z","updated_at":"2025-02-25T12:28:40.900Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer","source_id_and_acronym":"NCT05256225 - NRG-GY026","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 525","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-24"},{"id":"9c255554-467f-443d-b9bf-0883f980d302","acronym":"SGNB6A-001","url":"https://clinicaltrials.gov/study/NCT04389632","created_at":"2021-08-12T17:53:41.583Z","updated_at":"2025-02-25T13:53:17.348Z","phase":"Phase 1","brief_title":"A Study of SGN-B6A in Advanced Solid Tumors","source_id_and_acronym":"NCT04389632 - SGNB6A-001","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • sigvotatug vedotin (PF-08046047)"],"overall_status":"Recruiting","enrollment":" Enrollment 824","initiation":"Initiation: 06/08/2020","start_date":" 06/08/2020","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 02/28/2028","study_completion_date":" 02/28/2028","last_update_posted":"2025-02-20"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"efdddd68-b037-4a5e-906c-80c7cd541d58","acronym":"DOVE","url":"https://clinicaltrials.gov/study/NCT06023862","created_at":"2023-09-05T18:12:37.255Z","updated_at":"2025-02-25T13:13:29.101Z","phase":"Phase 2","brief_title":"A Three-arm Randomized Phase II Study of Dostarlimab Alone or with Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)","source_id_and_acronym":"NCT06023862 - DOVE","lead_sponsor":"Yonsei University","biomarkers":" MSI • PD-1 • WT1","pipe":"","alterations":" ","tags":["MSI • PD-1 • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • gemcitabine • paclitaxel • doxorubicin hydrochloride • Jemperli (dostarlimab-gxly) • pegylated liposomal doxorubicin"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 01/22/2024","start_date":" 01/22/2024","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-14"},{"id":"0259c6da-60cc-4165-a7fc-adacc10727ab","acronym":"NCI-2018-00438","url":"https://clinicaltrials.gov/study/NCT03552471","created_at":"2021-01-18T17:29:09.671Z","updated_at":"2025-02-25T15:10:50.793Z","phase":"Phase 1","brief_title":"Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03552471 - NCI-2018-00438","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 07/12/2018","start_date":" 07/12/2018","primary_txt":" Primary completion: 06/24/2022","primary_completion_date":" 06/24/2022","study_txt":" Completion: 12/19/2022","study_completion_date":" 12/19/2022","last_update_posted":"2025-02-13"},{"id":"527306d6-34b9-4ad0-b5f6-cf22600b56c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03968406","created_at":"2024-02-22T16:25:39.444Z","updated_at":"2025-02-25T15:11:11.864Z","phase":"Phase 1","brief_title":"Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers","source_id_and_acronym":"NCT03968406","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/26/2019","start_date":" 09/26/2019","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-13"},{"id":"757c7ea9-28ea-4973-bbc9-a09748839d13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05039801","created_at":"2021-09-10T16:57:15.373Z","updated_at":"2025-02-25T15:35:16.395Z","phase":"Phase 1","brief_title":"IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05039801","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2","pipe":" | ","alterations":" PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["PD-L1 • PIK3CA • PTEN • STK11 • ARID1A • NF1 • KEAP1 • PD-1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • ARID1A mutation • STK11 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Truqap (capivasertib) • IPN60090"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 05/29/2026","study_completion_date":" 05/29/2026","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"3f5aa33e-06f6-48ab-8a9d-748f65a29841","acronym":"NRG GY020","url":"https://clinicaltrials.gov/study/NCT04214067","created_at":"2021-01-18T20:31:12.388Z","updated_at":"2025-02-25T16:44:47.600Z","phase":"Phase 3","brief_title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer","source_id_and_acronym":"NCT04214067 - NRG GY020","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 04/09/2020","start_date":" 04/09/2020","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2025-02-06"},{"id":"577a4268-ea8b-44ef-b557-7019f2e329c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691504","created_at":"2023-01-20T16:00:14.081Z","updated_at":"2025-02-25T16:46:30.558Z","phase":"Phase 1","brief_title":"Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers","source_id_and_acronym":"NCT05691504","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • BCL2L1","pipe":"","alterations":" ","tags":["BRAF • BCL2L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • pelcitoclax (APG-1252)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/14/2023","start_date":" 09/14/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-05"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"0f2fd0d7-bcdd-47e9-87f0-2ecfc6cc8ea1","acronym":"PREFACE","url":"https://clinicaltrials.gov/study/NCT06799624","created_at":"2025-02-25T17:55:13.446Z","updated_at":"2025-02-25T17:55:13.446Z","phase":"","brief_title":"Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCEr","source_id_and_acronym":"NCT06799624 - PREFACE","lead_sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/21/2025","start_date":" 01/21/2025","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2025-01-29"},{"id":"607c59af-1fd9-4afc-8491-e33c116441ac","acronym":"PNeoVCA","url":"https://clinicaltrials.gov/study/NCT05269381","created_at":"2022-03-08T17:52:43.258Z","updated_at":"2024-07-02T16:34:26.810Z","phase":"Phase 1/2","brief_title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05269381 - PNeoVCA","lead_sponsor":"Mayo Clinic","biomarkers":" KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK","pipe":" | ","alterations":" TMB-H","tags":["KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Leukine (sargramostim) • neoantigen peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 02/24/2025","primary_completion_date":" 02/24/2025","study_txt":" Completion: 02/24/2026","study_completion_date":" 02/24/2026","last_update_posted":"2024-06-12"},{"id":"6ae91b16-28e3-42da-b2eb-0dd1d16d9e97","acronym":"","url":"https://clinicaltrials.gov/study/NCT05826015","created_at":"2023-04-24T14:03:55.315Z","updated_at":"2024-07-02T16:34:26.698Z","phase":"Phase 1","brief_title":"AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer","source_id_and_acronym":"NCT05826015","lead_sponsor":"Washington University School of Medicine","biomarkers":" HER-2 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["HER-2 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • batiraxcept (AVB-500)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 06/03/2029","primary_completion_date":" 06/03/2029","study_txt":" Completion: 06/04/2034","study_completion_date":" 06/04/2034","last_update_posted":"2024-06-12"},{"id":"c992b4e8-e799-41ef-b989-1921ae3a3287","acronym":"","url":"https://clinicaltrials.gov/study/NCT03556228","created_at":"2021-01-18T17:30:17.557Z","updated_at":"2024-07-02T16:34:59.667Z","phase":"Phase 1","brief_title":"Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma","source_id_and_acronym":"NCT03556228","lead_sponsor":"VM Oncology, LLC","biomarkers":" NTRK1","pipe":" | ","alterations":" NTRK1 fusion • NTRK1 mutation • NTRK expression","tags":["NTRK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK1 mutation • NTRK expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMD-928"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 06/08/2018","start_date":" 06/08/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-05-31"},{"id":"bcad0e5d-8e9a-4e78-8773-942d97532535","acronym":"FUCHSia","url":"https://clinicaltrials.gov/study/NCT03926936","created_at":"2021-01-18T19:20:57.374Z","updated_at":"2024-07-02T16:35:00.857Z","phase":"Phase 2","brief_title":"FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study","source_id_and_acronym":"NCT03926936 - FUCHSia","lead_sponsor":"Frederic Amant","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 12/27/2022","study_completion_date":" 12/27/2022","last_update_posted":"2024-05-27"},{"id":"84572fdb-bb5f-45fd-aa5f-f18dedb5e9a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05334069","created_at":"2022-04-19T23:53:56.743Z","updated_at":"2024-07-02T16:35:01.625Z","phase":"","brief_title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","source_id_and_acronym":"NCT05334069","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-23"},{"id":"8c77c515-8fd7-47a1-b2a0-d210db442390","acronym":"","url":"https://clinicaltrials.gov/study/NCT00977574","created_at":"2021-01-18T03:48:50.533Z","updated_at":"2024-07-02T16:35:03.140Z","phase":"Phase 2","brief_title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT00977574","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT1","pipe":"","alterations":" ","tags":["AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • temsirolimus • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • patupilone (EPO 906)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 09/14/2009","start_date":" 09/14/2009","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 03/06/2025","study_completion_date":" 03/06/2025","last_update_posted":"2024-05-17"},{"id":"bd3903e4-47f8-44a5-a2e7-496b069f8567","acronym":"","url":"https://clinicaltrials.gov/study/NCT02208375","created_at":"2021-01-18T10:20:36.481Z","updated_at":"2024-07-02T16:35:02.701Z","phase":"Phase 1/2","brief_title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","source_id_and_acronym":"NCT02208375","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ER • PGR • BRCA • MUC16","pipe":" | ","alterations":" BRCA mutation","tags":["ER • PGR • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Truqap (capivasertib) • vistusertib (AZD2014)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 159","initiation":"Initiation: 11/11/2014","start_date":" 11/11/2014","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-05-17"},{"id":"bf08ec17-5171-4452-9f04-c52123ce8ca4","acronym":"QUILT-3.017","url":"https://clinicaltrials.gov/study/NCT03476681","created_at":"2021-10-22T17:53:23.788Z","updated_at":"2024-07-02T16:35:03.580Z","phase":"Phase 1/2","brief_title":"Study of NEO-201 in Solid Tumors Expansion Cohorts","source_id_and_acronym":"NCT03476681 - QUILT-3.017","lead_sponsor":"Precision Biologics, Inc","biomarkers":" EGFR • PD-L1 • BRAF • TMB • MSI • ROS1 • ALK1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600","tags":["EGFR • PD-L1 • BRAF • TMB • MSI • ROS1 • ALK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • TMB-H • MSI-H/dMMR • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • NEO-201"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 01/18/2019","start_date":" 01/18/2019","primary_txt":" Primary completion: 10/15/2025","primary_completion_date":" 10/15/2025","study_txt":" Completion: 10/15/2026","study_completion_date":" 10/15/2026","last_update_posted":"2024-05-15"},{"id":"839b22a8-14fd-4988-8b4a-11a3d5056039","acronym":"HFB-301001-01","url":"https://clinicaltrials.gov/study/NCT05229601","created_at":"2023-05-01T16:04:27.454Z","updated_at":"2024-07-02T16:35:04.798Z","phase":"Phase 1","brief_title":"A Study of HFB301001 in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05229601 - HFB-301001-01","lead_sponsor":"HiFiBiO Therapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HFB301001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-09"},{"id":"7e75ac94-fd8b-42e6-8ac2-7780bc50078b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04038619","created_at":"2024-04-05T15:40:34.993Z","updated_at":"2024-07-02T16:35:05.277Z","phase":"Phase 1","brief_title":"Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients","source_id_and_acronym":"NCT04038619","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL6 • CD4","pipe":"","alterations":" ","tags":["IL6 • CD4"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-08"},{"id":"7331f3e4-ddb8-4e6b-be19-f240a3a397fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05092373","created_at":"2021-10-25T11:53:10.792Z","updated_at":"2024-07-02T16:35:05.611Z","phase":"Phase 1","brief_title":"Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax","source_id_and_acronym":"NCT05092373","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cometriq (cabozantinib capsule)"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 04/29/2022","start_date":" 04/29/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-05-07"},{"id":"7c21da8e-5d4d-49d2-b559-c9e8b999b515","acronym":"","url":"https://clinicaltrials.gov/study/NCT03987555","created_at":"2021-01-18T19:36:27.910Z","updated_at":"2024-07-02T16:35:06.257Z","phase":"","brief_title":"Paclitaxel Therapeutic Drug Monitoring in Cancer Patients","source_id_and_acronym":"NCT03987555","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/11/2019","start_date":" 11/11/2019","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-03"}]